Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma
Interview with David Henry MD
Related Articles
FDA Expands Enhertu Indication to HER2-Positive Solid Tumors
The agent had already been approved for several cancer types.
New Data: Black Women More Likely to Die From Common Endometrial Cancer Subtype
Black patients had more than two times the risk of dying from their cancer and they are underrepresented in clinical trials.
Plant-Based Diet a Boon for Men With Prostate Cancer
A diet of fresh vegetables and fruit with few animal-based products is linked to reduced risk for recurrent prostate cancer, says study.
Living in a Food Swamp Tied to High Breast Cancer Mortality
New research shows higher postmenopausal breast cancer mortality in communities with easier access to unhealthy fast food.
Factors associated with improved prognostic outcomes in locally advanced BC
Key clinical point: In women with locally advanced breast cancer (LABC) who received ne
Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy
This review summarizes prior data regarding adjuvant and neo-adjuvant chemotherapy in non-small cell lung cancer and elaborates on results from the newer trials
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut
Key Points. Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL.Adverse events oc
How I treat non-transfusion-dependent β-thalassemia
Saliba and colleagues use 4 illustrative cases to delineate diagnosis and treatment of non-transfusion-dependent β-thalassemia. The authors discuss their approa
SABR could defer systemic therapy in oligoprogressive breast cancer
“We found surprisingly that SABR delayed a change in therapy by 10 months, which is great for patients.”
What is the future for multicancer early-detection tests?
Liquid biopsies based on genomic biomarkers could make MCED a reality, especially for cancers for which there is no standard screening process.